Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Compared with DPP-4 inhibitors, elderly patients with type 2 diabetes had lower composite rates of heart attack, stroke, ...

Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...